Table 1. Characteristics of eligible studies.
Author | Year | Country | Ethnicity | Cancer | Sources of control | Genotyping method | Cases | Controls | Case | Control | Phwe | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSTO1 polymorphism | CC | CA | AA | CC | CA | AA | |||||||||
Granja13 | 2005 | Brazil | mixed | TC | PB | PCR-SSCP | 93 | 173 | 74 | 17 | 2 | 146 | 19 | 8 | <0.001 |
Bufalo21 | 2006 | Brazil | mixed | TC | PB | PCR-RFLP | 73 | 184 | 59 | 14 | 159 | 25 | |||
Olsen9 | 2008 | Denmark | Caucasian | BC | PB | PCR-RFLP | 396 | 396 | 121 | 199 | 76 | 123 | 210 | 63 | 0.089 |
Lima-Jr16 | 2008 | Brazil | mixed | PC | HB | PCR-SSCP | 125 | 100 | 116 | 6 | 3 | 92 | 4 | 4 | <0.001 |
Pongstaporn10 | 2009 | Thailand | Asian | ALL | HB | PCR-RFLP | 99 | 100 | 59 | 40 | 0 | 76 | 23 | 1 | 0.607 |
Wang11 | 2009 | Taiwan | Asian | UC | HB | PCR-RFLP | 520 | 520 | 368 | 135 | 17 | 356 | 153 | 11 | 0.243 |
Andonova15 | 2010 | Germany | Caucasian | BC | PB | MALDI-TOF MS | 1000 | 992 | 396 | 509 | 95 | 429 | 456 | 107 | 0.384 |
Chariyalertsak17 | 2009 | Thailand | Asian | BC | HB | PCR-RFLP | 101 | 151 | 80 | 20 | 1 | 117 | 33 | 1 | 0.414 |
Chung18 | 2011 | Taiwan | Asian | UC | HB | PCR-RFLP | 149 | 251 | 107 | 41 | 1 | 166 | 78 | 7 | 0.546 |
Beebe-Dimmer15 | 2012 | USA | Caucasian | UC | PB | Taqman | 212 | 266 | 97 | 98 | 17 | 123 | 113 | 30 | 0.601 |
Sanguansin20 | 2012 | Thailand | Asian | HNSCC | HB | PCR-RFLP | 300 | 299 | 231 | 67 | 2 | 234 | 62 | 3 | 0.619 |
Guzide ADA12 | 2013 | Turkey | Caucasian | LC | PB | PCR-RFLP | 172 | 214 | 82 | 77 | 13 | 104 | 87 | 23 | 0.456 |
Min-Che Tung29 | 2014 | Taiwan | Asian | UC | HB | PCR-RFLP | 300 | 233 | 230 | 70 | 150 | 79 | |||
GSTO2 polymorphism | AA | AG | GG | AA | AG | GG | |||||||||
Morari22 | 2006 | Brazil | mixed | OC | PB | PCR-RFLP | 69 | 222 | 24 | 37 | 8 | 87 | 104 | 31 | 0.993 |
Leite23 | 2007 | Brazil | mixed | SC | PB | PCR-RFLP | 88 | 124 | 37 | 38 | 13 | 40 | 62 | 22 | 0.811 |
Masoudi24 | 2009 | Iran | Asian | GC | PB | PCR-RFLP | 67 | 134 | 33 | 29 | 5 | 54 | 61 | 19 | 0.791 |
Pongstaporn10 | 2009 | Thailand | Asian | ALL | HB | PCR-RFLP | 99 | 100 | 57 | 34 | 8 | 63 | 30 | 7 | 0.208 |
Wang11 | 2009 | Taiwan | Asian | UC | HB | PCR-RFLP | 520 | 520 | 298 | 175 | 47 | 294 | 195 | 31 | 0.859 |
Masoudi25 | 2010 | Iran | Asian | BC | PB | PCR-RFLP | 181 | 181 | 74 | 75 | 32 | 80 | 78 | 23 | 0.561 |
Andonov15 | 2010 | Germany | Caucasian | BC | PB | MALDI-TOF MS | 1004 | 997 | 425 | 456 | 123 | 442 | 453 | 102 | 0.371 |
Chariyalertsak17 | 2009 | Thailand | Asian | BC | HB | PCR-RFLP | 101 | 151 | 59 | 38 | 4 | 86 | 60 | 5 | 0.155 |
Chung15 | 2011 | Taiwan | Asian | UC | HB | PCR-RFLP | 149 | 251 | 88 | 59 | 2 | 134 | 104 | 13 | 0.207 |
Masoud26i | 2011 | Iran | Asian | CRC | PB | PCR-RFLP | 63 | 126 | 30 | 25 | 8 | 52 | 55 | 19 | 0.482 |
Lesseur27 | 2012 | USA | Caucasian | UC | PB | CIGG | 658 | 928 | 255 | 321 | 82 | 398 | 439 | 91 | 0.057 |
Sanguansin20 | 2012 | Thailand | Asian | HNSCC | HB | PCR-RFLP | 300 | 299 | 170 | 112 | 18 | 171 | 109 | 19 | 0.771 |
Sohail28 | 2013 | Pakistan | Asian | BC | PB | PCR-RFLP | 100 | 102 | 0 | 10 | 90 | 7 | 28 | 67 | 0.105 |
PB: population-based; HB: hospital-based; Phwe: Hardy-Winberg equilibrium; TC: thyroid carcinoma; BC: breast cancer; PC: prostate carcinoma; ALL: acute lymphoblastic leukemia; UC: urothelial carcinoma; HNSCC: head and neck squamous cell carcinoma; LC: lung cancer; OC: ovarian carcinoma; SC: skin cancer; GC: gastric cancer CRC: colorectal cancer; CIGG: custom Illumina Golden Gate 96 SNP panel array.